FRANKLIN LAKES, N.J.,
Jan. 17, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced the commercial
availability of its new kits that provide an easier method to
identify and quantify genetic information in individual cells for
genomics-based research.
The process of whole transcriptome analysis (WTA) is typically
used by researchers in the discovery phase to determine if an
under- or over-expression of certain genes are indicative of a
specific set of physical characteristics, or phenotype. Being able
to quantify RNA molecules that comprise genes is a critical early
stage process to determine what makes healthy cells different from
diseased cells, for example, or to gain a greater understanding of
the underlying causes of cell differentiation.
BD Precise WTA kits include specialized reagents that can
extract RNA molecules from individual cells and then "tag" each
molecule with a unique molecular signature or "molecular index" to
enable researchers to count each individual instance of the
molecule and attribute the molecule to a specific cell. BD has over
40 years of experience analyzing proteins expressed on cell
surfaces through flow cytometry, which BD has paired with Precise
WTA kits to create a breakthrough offering. With this innovative
combination, BD is empowering researchers to overcome the inherent
limitations of current technologies and discover new connections in
cell biology.
"The BD Precise WTA kits provide researchers with more accurate
and easy-to-use genomics tools to enable more efficient
identification of genetic markers for disease," said Stephen Gunstream, vice president of Genomics
for BD. "The combination of our reagents, cell sorters and data
analytics enables BD to support researchers from sample preparation
to end data analysis."
Here's how it works:
- A sample obtained from biopsy or other method is stained with
dyes that attach antibodies to specific proteins on the surface of
the cells in the sample;
- The sample is put into a cell sorter, also known as a flow
cytometer, that can separate individual cells based on the color
emitted from the dyes, which indicates specific proteins are
present on the surface of the cell. BD Precise WTA reagents are
optimized for use with the BD FACS line of flow cytometers;
- The individual cells leave the cell sorter and are deposited in
one of 96 wells of a plate in the cell sorter that is pre-loaded
with the BD Precise WTA reagents;
- The individual cells in the plate are immediately lysed,
barcoded and further prepared for sequencing with BD Precise WTA
reagents;
- The sequencing data is processed and analyzed by a proprietary
analysis pipeline specific for RNA quantification for each cell
analyzed.
The result is a highly accurate quantification of RNA that
researchers can use to investigate biological questions from
diseases like cancer to stem cell development. Precise WTA is the
latest addition to the BD Precise product portfolio. Researchers
can use Precise WTA kits as part of the discovery phase and then
use Precise Targeted kits for efficient study of a smaller set of
gene targets to make the most of their research. BD Precise WTA
kits are currently available for research use only and not for
diagnostic or therapeutic use. For more information, contact BD at
+1 650.665.2400.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has more than 40,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
Contacts:
|
|
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-launches-reagents-to-simplify-single-cell-research-300391710.html
SOURCE BD (Becton, Dickinson and Company)